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1. Introduction 
Since 1941, when Huggins and Hodges proved the favourable effect of surgical castration 
and oestrogen administration on the progression of metastatic prostate cancer (PCa) (1,2), 
androgen deprivation therapy (ADT) became the mainstay of management of advanced PCa 
till now. They demonstrated for the first time the responsiveness of PCa to androgen 
deprivation. 
ADT effectively palliates the symptoms of advanced disease, significantly reduces tumor 
growth, but there is no conclusive evidence at present that it prolongs survival. Moreover, 
significant amount of data report that ADT is associated with several adverse effects. The 
most prominent include: loss of bone mineral density (BMD), which leads into increased 
fracture risk (3), induction of insulin resistance (4), unfavorable changes in serum lipid 
profile (5), changes in body composition (6) which can lead into increased cardiovascular 
morbidity (7) and changes in cognitive functions (8). 
The aim of ADT is to cause severe hypogonadism, and adverse effects of ADT clearly 
demonstrate the essential and pluripotent role of male´s most important androgen –
testosterone (TST).  
2. Testosterone: A basal overview of biosynthesis, metabolism and its action 
In the human male, the main circulating androgen is testosterone (TST). More than 95% of 
circulating TST is secreted by the testis (Leydig cells) which produce aproximately 6-7 mg of 
TST daily (9). The rest is secreted by the adrenal cortex, and very small quantities (especially 
pregnan derivatives) are formed by the cells of the brain (10).  
Physiologic TST level in a male is 3-8 ng / ml. The source for the synthesis of steroids is 
cholesterol. This substrate may be synthetized de novo from acetate but it may be also taken 
up from plasma lipoproteins. Cleavage of the side chain of cholesterol in the mitochondria 
and the formation of pregnenolone (biologically inactive) is the start of steroidogenic 
cascade. Pregnenolone is further converted into various steroids by enzymes (cytochromes 
P450) in the endoplasmatic reticulum. 
TST secretion is regulated by the hypothalamic-pituitary-gonadal axis. The hypothalamic 
luteinising hormone-releasing hormone (LHRH) stimulates the anterior pituitary gland to 
release luteinising hormone (LH) and follicle-stimulating hormone (FSH). The main 
regulator of Leydig cell function is LH, acting through the LH receptor (LHr) in Leydig cells. 
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LH and FSH are required for the development and maintance of testicular functions.The 
natural ligand for the LHr is LH, but also human choriogonatropin (hCG) can equally well 
activate the LHr. Activated LHr stimulate adenylyl cyclase via GTP binding proteins and 
this results in increased production of cyclic AMP (cAMP). cAMP increases steroid 
production (11). 
The total concentration of steroids in target tissues (central and peripheral nervous system, 
bone, muscle, adipose tissue, haematopoetic system and myocardium) and body fluids is 
dependent on the presence of binding proteins (sex hormone binding globulin, SHBG, 
albumin). Binding proteins represent a storage form of circulating steroids, which bind 98% 
of circulating TST. The rest-2% is "free testosterone" (fTST), which is biologically active. 
Homeostasis is achieved by “closed” steroid feedback inhibition mechanism, where the 
plasmatic level of steroids affects the secretion of LH from adenohypophysis. 
The effect of TST on target tissues is modulated by metabolic pathways. 
1. Aromatisation of TST gives rise to 17b- estradiol. When the target cell is estrogen-
dependent, the aromatase activity in target cells and supply of androgen substrate 
(TST) are of major importance for determining the rate of synthesis of estrogens. 
Aromatase cytochrome P450 enzyme is expressed in many tissues including placenta, 
ovary, testis, fat tissue, liver, brain, hair follicles.  
2. Reduction of TST into 5-alfa-dihydrotestosterone (DHT) is achieved by 5a-reductase. 
This active form of TST (5 to 10 times more biologically effective) can fully activate the 
androgen receptor (AR) (12). There are 3 isoforms of 5a-reductase. Isoform 2 is clinically 
more important because its deficiency is associated with distinct clinical manifestations 
(13). Isoform 2 predominates in cells of the prostate and external genitalia, while 
isoform 1 predominates in the cells of the skin (except genitals), and in liver cells in 
small amounts. However, in prostate cancer cells, overexpression of isoform 1 is a 
common finding, thus increasing its clinical significance (14). In the total deficiency of 
isoform 2 (autosomal recessive) there is a serious alteration of the development of sex 
organs in utero (male pseudohermafroditism). Many mutations of the gene encoding 
isoform 2 are known and can result into a number of different clinical manifestations. 
Signs of its deficiency are small phallus, severe hypospadias, scrotum bifidum, residual 
prostate utriculus (15). The newly discovered isoform 3 may play an important role in 
the development of hormone-refractory prostate cancer (HRCaP) as its overexpression 
is found in the HRCaP cells (16). 
In addition to these metabolic pathways, the level of DHT in target tissues is affected by 
other enzymes (hydroxysteroid dehydrogenases), which "fine-tune" the effect of androgens 
in the target tissues (17). Owing to these local conversions the peripheral plasma 
concentration of androgens are only a rough indicator for their biological activities (12).  
The mechanism of action of androgens can be divided into genomic and non-genomic effect 
(12). Non - genomic effects of androgens include mechanisms affecting the flow of calcium 
in the cells and the effect on phosphorylation cascade of Map-kinase (18, 19), or membrane 
effects (20). Genomic effects are mediated by activation of androgen receptor (AR). AR acts 
as a transcription factor activated by its ligand (TST). By androgen binding, AR is 
translocated from the cytoplasm to the nucleus where it binds to its DNA domain and 
interacts as a homodimer with specific DNA sequences that are referred as androgen 
responsive elements (ARES) (21). Its binding to DNA leads into interactions with 
transcription factors (22) and other co-factor proteins (21). This results into the "up" or 
"down" regulation of transcription of target genes (23). 
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Androgen metabolites are excreted as free steroids or bound (conjugated). Conjugated 
steroids are bound to glucuronide or sulfate group. Androgens are mostly degraded in the 
liver (glucuronate, sulphates), but the prostate the skin also contribute significantly to the 
metabolism of androgens. All the steroid - metabolising enzymes constitute a network for 
transforming androgens into secretion products (conjugated, unconjugated) that finally 
leave the body via the urine or the skin. The flux though this network is great, because the 
half-life of TST in men is only 12 minutes (12). 
3. Androgens and bone metabolism 
Growth and resorption of bone tissue are mediated by osteoblasts and osteoclasts. Both types 
of cells exert mutual influence on each other and equilibrium between the activity of both 
cell lines maintains net bone mass during constant renewal and turnover. Decreased 
osteoblast activity and increased activity of osteoclasts leads into loss of bone mass. AR have 
been located on normal human osteoblasts (24) and both aromatizable and non-
aromatizable androgens can stimulate of human osteoblasts proliferation in vitro (25). 
Bone deformation strain represents a stimulus for osteoblastic activity. Androgens modify 
the effects induced by the mechanoreception of human osteoblastic cells by affecting 
adhesion molecule expression, i.e. fibronectin and the fibronectin receptor. These substances 
facilitate the adhesion of bone cells to the extracellular matrix, which represents a crucial 
requirement for osteoblastic development and function (26). In addition, the secretion of 
osteoprotegerin (OPG), which is unaffected by mechanical strain alone, is doubled when 
this stimulus occurs in the presence of androgens. OPG is a decoy receptor for RANKL 
(receptor activator of nuclear factor-kappaB ligand). RANKL is secreted by osteoblasts, it 
induces osteoclastogenesis stimulates osteoclast differentiation (27). Thus, OPG inhibits 
bone resoptive effect induced by RANKL (26). Accordingly, TST levels directly correlate 
with OPG concentrations in healthy men (28). 
Parathyroid hormone (PTH) induces osteoclast formation a differentiation. Androgens have 
direct inhibiting effect on this process via osteoclasts, which express AR and these cells are 
also blocked form PTH effects by androgens when no conversion to estrogens occurs (29).  
Androgens decrease the number of bone remodeling cycles by modifying the genesis of 
osteoclasts and osteoblasts from their respective progenitor cells. In addition, androgens 
also exert effects on the lifespan of mature bone cells: they exert pro apoptotic effects on 
osteoclasts and anti-apoptotic effects on osteoblasts and osteocytes. TST also modulates 
effects induced by other hormones and cytokines involved in bone metabolism (30). 
Osteoblast activity is reflected by concentration of procollagen type 1 (carboxy-terminal: 
P1CP or amino-terminal: P1NP) and other non collagenous proteins secreted by osteoblasts, 
eg. osteocalcin and bone specific alkaline phosphatase (BSAP). Also OPG as a decoy 
receptor for RANKL, can serve as marker of osteoblast activity. Bone resorption, hence 
osteoclast activity, therefore, can be estimated by urinary excretion of degradation products 
of type I collagen, such as deoxypyridinoline (DPD) and collagen type I cross- linked N-
telopeptide (NTX) (31). 
An independent role of androgens in protecting bone mass, both by promoting bone 
formation and attenuating bone resorption has been demonstrated in humans. Nevertheless, 
the role of its metabolite estradiol is pivotal in bone metabolism (30). 
Aromatization of TST to estradiol is a pivotal event concerning effects of sex steroids on 
bone metabolism. Estrogen receptors (ER) have been localized in human osteoblasts (32), 
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osteoclasts (33), and osteocytes (34). Human males with mutations of ER or aromatase genes 
do not achieve normal bone density, despite normal or increased levels of serum TST (35). 
4. Androgen deprivation therapy (ADT) and its side effects 
ADT is increasingly attained through the use of luteinizing hormone-releasing hormone 
(LHRH) agonists, which down-regulate anterior pituitary receptors and lead to therapeutic 
hypogonadism, or directly by inhibiting pituary receptors by LHRH antagonists. The 
standard castration level is < 50 ng/dL. Prostate cells are physiologically dependent on 
androgens which stimulate its growth, function and proferation. TST, although not 
tumorigenic, is essential for the growth and perpetuation of tumor cells (36).  
Prostate cancer (PCa) displays a range of clinical behavior, from slow-growing tumors of no 
clinical significance to aggressively metastatic and lethal disease. Most PCa cases diagnosed 
with present diagnostic techniques fall into the moderately differentiated group (grade 2, 
Gleason 6), of which the cancer-specific 10–15-year mortality is 18–30%. This is even lower 
in the group of PCa diagnosed with grade 1 and 2 or Gleason 4–6, and there are subgroups 
of patients who are not at risk of dying from PCa even within 15years. Overall mortality is 
then determined by comorbidity (37). While both short- and long-term ADT are effective for 
treating PCa, it can often have significant side-effects. It is important that these 
complications are recognized and managed appropriately so that adverse effects on the 
patient's quality of life (QoL) are minimized. There has been an increase in the use of ADT at 
all stages of PCa in recent years. The extensive use of ADT is raising concerns about adverse 
effects – loss of BMD being the most prominent.  
5. Bone loss and osteoporosis 
As shown above, androgens are important for maintenance of bone tissue. Although ADT is 
used in medical practice for more than 60 years, it’s only few years that the clinicians 
became aware of serious and potentially catastrophic consequences resulting form long-
term ADT. 
Bone density is determined both by peak bone mass achieved during skeletal development 
and the subsequent amount of maintenance and resorption of bone tissue. Androgens affect 
both processes and thus are a pivotal determinant of bone mass in men.  
5.1 Osteoporosis 
Osteoporosis is defined as a systemic metabolic bone disease characterized by low bone 
mass density (BMD) and microarchitectural deterioration of bone tissue, with a consequent 
increase in bone fragility and susceptibility to fracture (38). Diagnosis of osteoporosis based 
on WHO definitions is developed for women originally (39). When based on male cutoffs, 1-
2 million (3 - 6%) of men have osteoporosis and 8 -13 million (28 - 47%) have osteopenia; 
when based on female cutoffs, 280,000 - 1 million (1 - 4%) have osteoporosis and 4 - 9 million 
(15 - 33%) have osteopenia (40, 41). While this numbers may seem disturbing, it is believed 
that osteoporosis in men is substantially underdiagnosed and undertreated in the United 
States (42). 
Female osteoporosis has been studied extensively and characterized due to its high 
prevalence (43) whereas male osteoporosis, especially that associated with ADT has gained 
focus only recently. 
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In men, osteoporosis occurs later than in women (44), but the prevalence of osteopenia does 
not differ significantly between men and women aged more than 50 years. Conversely, the 
prevalence of osteoporosis in men is lower than in women (40). Even though it may be 
underestimated when standard female BMD parameters are considered suitable for normal 
mineralization in men (45). Men generally have a higher BMD than women at the same age 
(46). Accordingly, the prevalence of male osteoporosis is greater when male-specific ranges 
are used in men above fifties: ranging from 1% to 4% of elderly men when the diagnosis is 
based on female cut-off points vs. 3% to 6% when based on male cut-off points (40). 
Men are estimated to lose bone mineral density (BMD) at a rate of up to 1% per year with 
advancing age (47, 48), and one in eight men over age 50 years will experience an 
osteoporosis-related fracture in their lifetime (49). Of all osteoporotic fractures, hip fractures 
contribute to the greatest morbidity as well as mortality, both of which are much greater in 
men than in women (50-52). 
5.2 Diagnosis of osteoporosis 
Current guidelines recommend assessment of bone mineral density (BMD) previous to ADT 
and yearly thereafter (53) with dual-energy x-ray absorptiometry (DXA) which is considered 
the standard method to measure BMD (54). International Society for Clinical Densitometry 
(ISCD) recommends that central skeleton sites (lumbar spine, total hip and femoral neck) are 
the most appropriate locations to asses BMD (55). 
Diagnosis of osteoporosis can than be made according to WHO classification: if T- score is 
less than 2,5 of standard deviation. Values between (-) 1 and (-) 2.5 SD (standard deviation) 
is defined as osteopenia. T - score stands for the number of standard deviations (SD) from 
the density of young healthy individuals of the same sex (39).(Table 1) 
To improve the identification of patients at highest risk of fracture, WHO has developed an 
algorithm to predict fractures - FRAX ™ http://www.shef.ac.uk/FRAX/  
According to European Association of Urology (EAU) guidelines, a precise evaluation of BMD 
should be performed by dual X-ray absorptiometry before starting long-term ADT. An initial 
low BMD (T-score below 2.5, or below 1 if other risk factors are present) indicates a high risk of 
subsequent non-metastatic fracture, suggesting the need for early use of preventive 
bisphosphonate therapy (56). 
 
Clasiffication T-score 
Normal >-1 
Osteopenia -1 - -2,5 
Osteoporosis <-2,5 
Table 1.  
5.3 ADT, prostate cancer (PCa) and clinical aspects of bone disease 
At presence, significant amount of data report that ADT is associated with the loss of 
BMD in a time-dependent manner (57-59) which leads into increased fracture risk (60). 
Skeletal fractures negatively correlate with overall survival in men with PCa (61) and 
maintaining skeletal health is crucial for QoL and survival (62).  
Treatment of complications of pathological fractures is complicated and expensive (63). 
Moreover, the typical feature of PCa is the ability to metastasize into bone in more than 80 % 
of cases (64). Most bone lesions in PCa are osteoblastic in nature (65). However, studies 
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show that osteoblastic lesions in PCa have excessive bone growth, but on the other hand 
also simultaneously increased osteolysis (66). The new bone formed by tumor stimulated 
osteoblast is weak and poorly mineralized and subsequent osteopenia leads into increased 
osteolysis - result to the creation of bone matrix with seriously compromised integrity. The 
risk of developing bone complications is therefore increased. 
Treatment of PCa does not focus on skeletal complications that may arise from bone 
metastases. The main symptom of bone metastases is severe bone pain, which often requires 
strong narcotic therapy or palliative radiation therapy. Other complications include spinal 
cord compression and pathological fractures, which may require surgery. These skeletal 
complications have a negative effect on QoL (65). 
Data from a double-blind, placebo-controlled studies show that approximately half of 
patients treated with ADT had one or more events associated with the skeleton. Most of 
these events required palliative radiotherapy, or were pathological fractures (67). Skeletal 
complications are also associated with significant financial expenditure. A recent analysis of 
the costs of health insurance in the U.S. since 1994 until 2002 revealed that the total cost to 
treat patient with PCa who had skeletal event were 20 000 dollars higher than in patient 
who did not experience skeletal event (68). 
Interestingly, it has been reported that hormone naive patients with advanced PCa have 
lower baseline BMD than healthy control, and relatively high prevalence of osteopenia 
and osteoporosis (69, 70). The largest study that investigated the association of BMD 
measures with PCa risk in older men enrolled was the Osteoporotic Fractures in Men 
Study (MrOS) (71). 
MrOS was prospective study conducted on 4597 men with mean follow up 5.2 years, 
which evaluated the association of BMD and incidental PCa in a cohort of older men with 
no history of PCa. Unexpectedly, the authors found that higher total body BMD was 
significantly related to reduced risk for PCa. This result was „unexpected“ because 
authors presumed that the higher levels of androgens lead into higher prevalence of PCa, 
which positively correlates with BMD. Additionally, total body BMD was inversely 
associated with the development of high-grade, but not low-grade disease. A similar but 
weaker association was observed for total hip BMD with high-grade PCa. This study 
confirms the association, although still not elucidated, between low BMD and PCa.  
5.4 Treatment of ADT induced osteoporosis 
Lifestyle changes: Immobilization is an important cause of bone loss. Immobile patients lose 
bone mass more rapidly than mobile patients. Regular daily activities, overcoming 
gravity, walking, and exercise have a positive impact on bone density: it stimulates 
osteoblasts to produce new bone and inhibits osteoclasts, thereby decreasing resorption of 
bone. It also improves physical coordination (prevention of falls). Cessation of smoking, 
decreased alcohol consumption and normalization of body mass index (BMI) helps to 
maintain BMD (72). 
Ca supplementation: The ideal is to ensure that the amount of calcium is taken in the 
normal diet. If the patient is unable to take the recommended amount of calcium in the 
diet (lactose intolerance, hyperlipoproteinemia, etc) it is recommended for calcium 
supplementation (1000mg – 1500 mg daily) (72). 
Vitamin D: Supplementation of vitamin D is recommended when its deficiency can be 
assumed or proven. The recommended daily dose is 400-800 IU (10-20 mg). 
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Bisphosphonates are one of the most potent inhibitors of bone resorption. The effect on the 
reduction of osteoporotic fractures has been demonstrated for treatment with alendronate, 
risedronate, ibandronate, etidronate and zoledronic acid. The effectiveness in reducing 
vertebral and nonvertebral fractures were confirmed by many studies (73, 74, 75). The 
optimal regimen for zoledronic acid is unclear, because one study recommends treatment 
every 3 weeks (76), while another trial has produced similar results with an annual injection 
(77), and finally, another study reports that single infusion of zoledronic acid in patients 
receiving ADT reduces bone mineral loss and maintains BMD at least for 12 months during 
ADT (78).  
One of the most important and serious adverse effect of bisphoshonate administration is jaw 
necrosis (79) The initial BMD could be used to guide the choice of regimen (80).Thus, a 3-
month injection might be given in osteoporotic patients, for whom a yearly injection is likely 
to provide insufficient protection (56). 
Denosumab is a fully human monoclonal antibody against RANKL (see above). In the largest, 
well conducted study to date, denosumab was associated with 5.6% increase in the lumbar 
BMD versus 1% decrease in the placebo arm. There were also significant BMD increases at 
the total hip, femoral neck and distal third of the radius. 60 mg was delivered 
subcutaneously every 6 months, was not associated with any significant toxicity, or delayed 
healing in vertebral fractures (81). 
6. Androgens and cognitive functions 
It is known that during certain developmental stages- especially during the first years of life, 
during adolescence, girls surpass in boys several verbal skills. Males excel after about the 
tenth year of life in non-verbal skills in adulthood, especially in spatial orientation and 
manipulation (82). 
Evidence of a link between sex hormones and spatial abilities came from studies of 
individuals with Turner syndrome (XO karyotype, no gonadal hormones) or testicular 
feminization syndrome- (XY karyotype, the tissues are refractory to normal levels of TST). 
These patients have female external genitalia, they are raised as girls. In these patients 
verbal skills surpass their spatial abilities, which is a typical pattern of cognitive abilities of 
women (83). 
Studies on men with idiopathic or acquired hypogonadotrophic hypogonadism confirm the 
importance of TST for spatial abilities. Short-term androgen supplementation did not restore 
spatial function, suggesting that low levels of sex hormones during the intrauterine and 
neonatal period have a lifelong impact (84).  
Direct sex hormones manipulation supports the conclusion that androgens play an 
important role in cognition. The first experiments with direct hormonal manipulation can be 
traced back to 1941 when Simonson et al. (85) published their experiment using methyl TST 
that was administered to eunuchoids, castrated males, and elderly men. The result was an 
improved ability to perceive the flicker (critical flicker frequency), a measure of attention 
and alertness, as long as the androgen treatment lasted (86). 
Androgen therapy was also administered to female to male transsexuals in high doses as a 
preparation before gender reassignment. Their spatial skills have significantly improved, 
while verbal skills declined considerably (87).  
For ethical reasons, nowadays the manipulation of gonadal hormones is restricted to 
patients in clinical studies. Thus, the last such study was conducted in 1971. Klaiber et al. 
(88) studied the effect of infused TST on mental abilities in healthy male students. After a 4-
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hour infusion of TST or saline in the control group, performance of the control group (saline 
infusion) showed a significant decline in mental performance when compared to TST 
infused group. 
6.1 Potential mechanisms of action 
TST may impact cognition through several mechanisms. For example, activation of calcium 
channels in the brain occurs through rapid, nongenomic methods of action on G-protein-
coupled, agonist sequestrable testosterone membrane receptors that initiate a 
transcription-independent signal pathway (89). TST also may impact cognitive 
performance directly through modulating neurotransmitters and stimulating neuronal 
connectivity, decreasing β-amyloid peptide production, and preventing N-methyl-D-
aspartate excitotoxicity (90) mechanisms implicated in cognitive disorders such as 
Alzheimer disease or dementia. Furthermore, some estrogen studies have highlighted 
several possible mechanisms through which this hormone can impact cognitive 
functioning (91). These include increasing cholinergic activity through its action of choline 
acetyltransferase, maintenance of dendritic spine density on CA1 pyramidal cells of the 
hippocampus and facilitating induction of long-term potentiation in the hippocampus, 
increasing serotonergic and cholinergic activity to maintain neural circuitry, altering 
lipoprotein, and decreasing risk of cerebral ischemia (92, 93). 
6.2 Cognitive functions and ADT 
Green et al were the first to systematically research the impact of androgen-ablation therapy 
on the cognitive functioning of men with PCa. Sixty-five men (mean age, 73 years) with 
advanced PCa were assigned randomly to 1 of 4 groups: leuprolide (N = 19), goserelin (N = 
20), cyproterone acetate (N = 11), and monitoring without hormone treatment (N = 15). All 
men participated in a battery of neuropsychological assessments at baseline (ie, 1 week 
before treatment) and then 6 months later. PSA and TST levels decreased significantly from 
baseline to 6 months for the 3 hormonally treated groups. Conflicting results emerged in the 
memory domain; men in the goserelin group surprisingly improved on 2 measures of 
memory (verbal [Wechsler Memory Scale-Revised] and visual [Rey-Osterrieth Complex 
Figure test]) but declined in another measure of verbal memory (Auditory Verbal Learning 
Test). The goserelin group also declined in a measure of executive functioning (Trails B). Of 
the 50 men on active treatments, 24 men showed a reliable decline (ie, >1 standard 
deviation) on at least 1 cognitive task, and 7 men showed a reliable change on 2 tasks, 
whereas the monitoring-only group showed no decline on any of the tasks (94). 
Salminen et al researched the cognitive effects of ADT on 26 men who were diagnosed 
recently with PCa and who began ADT 2 months before radiotherapy. From baseline to 12 
months, tests of visuomotor speed and of reaction time saw significant decreases. The 
decline in TST coincided with a decline in visuomotor processing (digit symbol), reaction 
time (10-choice reaction time), working memory speed (subtraction), sustained attention 
(vigilance), and recognition speed (recognition of letters) (95).  
Jenkins et al assessed 32 men with standard neuropsychological assessments at 3 time 
intervals: at baseline, 3 months, and 9 months. The average age of these men was 67.5 
years, and they used ADT for 3 to 5 months. Twenty-five healthy men, similar in age, 
served as the control group. Although there was no overall group effect, a greater percent 
of men in the ablation group reported a significant cognitive decline in 1 task (47%) 
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compared with the control group (17%; odds ratio, 4.412; P < .05) at the 3-month time 
point. There were no significant differences between the groups at the 9-month time 
point. On specific domain analysis, the tasks most impacted at the 3 month time point 
were spatial memory and ability (96). 
Joly et al compared physical and cognitive function in a cross-sectional study of 57 patients 
who were receiving ADT for nonmetastatic PCa and 51 healthy, age-matched controls. 
Thirty patients received ADT as adjuvant treatment after prostatectomy or radiotherapy, 
and 27 patients received ADT for increasing levels of PSA. The median duration on ablation 
therapy was 1.8 years (range, 0.4-7.4 years). To assess cognitive functioning, the researcher 
administered the Sensitivity Cognitive Screen and a self-reported assessment on cognitive 
deficits (the Functional Assessment of Cancer Treatment-Cognitive Scale [FACT-COG]). In 
contrast to other studies cited above, Joly and colleagues observed that, although men with 
nonmetastatic PCa who received ADT experienced more treatment-related symptoms, no 
differences in cognitive function on either the High Sensitivity Cognitive Screen or the 
FACT-COG. The authors suggested that the High Sensitivity Cognitive Screen may not be 
sensitive enough to detect the subtle cognitive changes that occur after ADT. In addition, 
self-report of cognitive function has not been correlated consistently with actual 
neuropsychological testing (97). 
In conclusion, the data show that androgen ablation does have cosequences for cognitive 
functioning. Larger longitudinal studies are warranted. 
6.3 ADT and changes in body composition 
Male hypogonadism (of any etiology) results in a decline in lean body mass (LBM) and an 
increase in fat mass, which is reversed with TST replacement (98). A cross-sectional study 
showed that men undergoing long-term ADT (12–101 months) have increased fat mass in 
the trunk and all extremities- measured by dual-energy x-ray absorptiometry (DXA), 
compared with eugonadal men with PCa not undergoing ADT (treated with prostatectomy 
and/or radiation therapy) and age-matched eugonadal controls (99).  
Another case control study examined the prevalence and magnitude of obesity and fat mass 
in a group of 62 men with PCa receiving ADT for 1–5 yr (100). Healthy men (n = 47) with a 
PSA of less than 4.0 ng/ml were recruited as controls. The study showed that men with PCa 
had significantly higher body weight (86.5 vs. 80.6 kg) and percent body fat (30 vs. 26%) 
than controls. 
Meta-analysis of sixteen studies showed that ADT increased percentage of body fat by on 
average 7.7% (95% CI 4.3, 11.2, from seven studies, P < 0.0001) and decreased % LBM by 
on average -2.8% (95% CI -3.6, -2.0, from six studies, P < 0.0001) but for both there was 
marked heterogeneity between studies (I2 = 99% I2 = 73%, respectively). Similarly, body 
weight (2.1%, P < 0.0001 from nine studies) and BMI (2.2%, P < 0.0001, from eight studies) 
increased significantly. More extensive changes were seen with longer duration of 
treatment (101).  
These studies prove that ADT results in an unfavorable body composition. The increase of 
fat mass in patients on ADT correlates positively with rising insulin levels (102). Hence, this 
increasing adiposity may be the primary event leading to these metabolic complications 
(possibly via elaboration of adipokines and inflammatory cytokines). Similarly, it is possible 
that a decrease in muscle mass may result in decreased glucose uptake by the muscle. These 
changes may ultimately lead to insulin resistance and diabetes in this population, hence 
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predisposing them to cardiovascular disease. Lifestyle changes or suitable interventions to 
minimize the effect of ADT on body composition need to be investigated. 
7. ADT and insulin resistance 
Epidemiological studies have shown that low TST levels predict the development of insulin 
resistance and type 2 diabetes (103, 104, 105). Studies have also confirmed a direct 
relationship between serum TST and insulin sensitivity (106). These findings are further 
supported by interventional studies showing an improvement in insulin sensitivity with 
TST replacement in hypogonadal obese men (107). 
7.1 Early metabolic changes  
There is some evidence, that the onset of insulin resistance can be detectable after 3 months 
of ADT (108, 109). 3-month prospective study using combined androgen blockade with 
leuprolide and bicalutamide showed a 43% increase in fat mass and a 26% increase in 
insulin levels from baseline, again indicating development of insulin resistance with 
increasing adiposity (110). Although there was no significant change in fasting glucose 
levels, a statistically significant increase in glycosylated hemoglobin was seen (though this 
increase was within the normal range from 5.46–5.62%). These observations suggest that 
insulin resistance develops within a few months of initiating ADT; however, this 
compensatory hyperinsulinemia prevents the development of diabetes. 
7.2 Late metabolic changes 
Observational study of a population-based cohort found that men undergoing ADT with 
GnRH agonists had a higher risk of incident diabetes (11%), coronary artery disease 
(25%), myocardial infarction, and sudden death (111). Interestingly, orchiectomy was 
associated only with a higher risk of diabetes. In some men, this risk was evident within 4 
months of starting ADT. These findings suggest that although both medical and surgical 
modalities of ADT result in increased metabolic burden, GnRH analogs are also 
associated with cardiovascular events. 
After 12 months of ADT, serum fasting glucose increased significantly (112), suggesting that 
men with PCa who are receiving long-term ADT are at risk for developing insulin resistance 
and hyperglycemia, thus leading to their increased risk of cardiovascular disease (113).  
A retrospective study which enrolled 396 patients with a median follow-up of 60.1 
months, 36 (11.3%) patients developed new- onset diabetes mellitus (NODM). In 77 
patients with pre-existing diabetes, there was an increase of >/=10% in serum HbA1c or 
fasting glucose levels in 15 (19.5%) and 22 (28.6%), respectively. On multivariate analysis, 
a BMI of >/=30 kg/m(2) was associated with an increased risk of developing NODM 
(odds ratio 4.65, P = 0.031) (114).  
In conclusion, patients receiving ADT for PCa with or with no history of diabetes should 
have routine surveillance of glycaemic control, with appropriate preventive and treatment 
measures. 
8. ADT and lipid alterations 
Hyperlipidemia is a known risk factor for cardiovascular disease. Recent epidemiological 
research suggests that low serum TST levels in men are associated with an adverse lipid 
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profile, especially elevated total cholesterol, LDL cholesterol, and triglycerides (115). 
Furthermore, interventional studies have shown that TST replacement in hypogonadal men 
results in an improvement in lipid profile (116). 
During long-term ADT, triglycerides rise by approximately 26% and total cholesterol 
approximately 10%. (117, 118, 119) In addition, high-density lipoprotein (HDL) rises 
approximately 8% to 11%. The net effect of these changes on cardiovascular risks is 
unknown. Significant changes can be observed within the first 3 months of treatment, with 
more modest subsequent change (110). 
9. ADT, metabolic syndrome and cardiovascular disease 
Metabolic syndrome (MS) is a known risk factor for cardiovascular disease (CVD) (120). 
According to the Adult Treatment Panel III guidelines (121), a man is considered to have MS 
if he meets 3 of the following 5 criteria: fasting plasma glucose level >110 mg/dL, serum 
triglyceride level 150 mg/dL, serum high-density lipoprotein level <40 mg/dL, waist 
circumference >102 cm, and blood pressure ≥ 130/85 mmHg.  Subjects on antihypertensive 
and antilipid medications are also considered positive for the respective criteria. Recently, 
male hypogonadism has surfaced as an independent risk factor for MS. Cross-sectional 
studies have shown that men with hypotestosteronemia have a higher prevalence of MS 
(122). Longitudinal studies also show that lower androgen levels in men independently 
predict the development of MS (105). 
These observations suggest that profound hypogonadism due to ADT imparts increased 
metabolic burden. Long-term prospective studies are needed to determine the time of onset 
of various metabolic alterations in these men. 
Since MS is associated with CVD, large studies were conducted to assed the CV risk and 
ADT. A large SEER-Medicare–based analysis of 73,196 men aged 66 years and older with PCa 
identified significant GnRH agonist-associated elevations in risk for myocardial infarction 
(HR, 1.11; p= .03), sudden cardiac death (HR, 1.16; p = .004), and new diagnosis of coronary 
heart disease (HR, 1.16; p< .001) (123). Similarly, a second SEER-Medicare–based study of 
23,000 men with PCa found a 20% ADT-attributable rise in CV morbidity at 1 year (124). 
In contrast, a recently reported matched cohort analysis of approximately 20,000 men in an 
On-tario database found no association between ADT and acute myocardial infarction (HR, 
0.91; 95% CI, 0.84–1.00) (125). 
A smaller population-based observational study of 3262 men who had undergone 
prostatectomy for PCa found that ADT was significantly associated with CV mortality, 
although only in the subset of men aged 65 years and older (126). This analysis failed to 
validate baseline coronary artery disease and diabetes as risk factors for CV mortality. 
Finally, combined analysis of 3 randomized trials involving men with localized PCa found 
that in the subset of men aged 65 years and older, 6 months of treatment with a GnRH 
agonist led to earlier onset of fatal myocardial infarction (127). 
Three large randomized, controlled trials by the Radiation Therapy Oncology Group 
(RTOG) have been retrospectively analyzed for an association between neoadjuvant/ 
concomitant/adjuvant ADT and CV mortality. These analyses have not found convincing 
evidence of an association (128-130). Secondary analyses of a randomized controlled trial 
from the EORTC found no association between ADT and CV mortality. The RTOG and 
EORTC trials were randomized, featured large enrollments, and had long-term follow-up. 
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Bone metabolism Loss of BMD, skeletal events (fractures), increased 
morbidity&mortality 
Bone marrow Anaemia 
Lipid profile alterations Increased: overall cholesterol, TAG, LDL, HDL 
Impaired insuline sensitivity Hyperinsulinemia, new onset diabetes, worsening existing 
DM  
Body composition Increase in fat mass, decrease in muscle mass, increased 
BMI 
Cardiovascular disease Increased risk of CV morbidity and mortality (?) 
Metabolic syndrome See above 
Cognitive functions Impaired spatial cognition, reaction time, other (?) 
Other Mood changes, loss of libido 
Table 2. Summary of main organ systems affected by severe hypogonadism (by ADT) 
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